Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
14.80
-0.22 (-1.46%)
At close: May 15, 2026, 4:00 PM EDT
14.79
-0.01 (-0.07%)
After-hours: May 15, 2026, 5:59 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
27.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Kyntra Bio | 34 |
| Palatin Technologies | 29 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| BriaCell Therapeutics | 16 |
| Apollomics | 14 |
PLRZ News
- 3 days ago - Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TheFly
- 3 days ago - Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - GlobeNewsWire
- 5 days ago - Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection - PRNewsWire
- 12 days ago - Polyrizon amends patent application claims for intranasal drug delivery platform - TheFly
- 12 days ago - Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform - GlobeNewsWire
- 18 days ago - Polyrizon Ltd trading halted, volatility trading pause - TheFly
- 18 days ago - Polyrizon Ltd trading resumes - TheFly
- 19 days ago - Polyrizon files European patent application for Trap & Target platform - TheFly